Innocan Pharma (INNPF) EBITDA Margin (2024 - 2025)
Innocan Pharma (INNPF) reported EBITDA Margin of 32.08% for the quarter ended Dec 31, 2025, up 2.80 percentage points from 29.27% a year earlier and up 49.77 percentage points from the prior quarter.
Powered by 
Analysis
Innocan Pharma (INNPF) EBITDA Margin (2024 - 2025) Analysis & Trends
For the year ended Dec 31, 2025, Innocan Pharma posted EBITDA Margin of 4.87%, up 0.52 percentage points from the prior year.
- By year, EBITDA Margin came in at 4.36% in the year ended Dec 31, 2024 (-23.73 pp) and 28.09% in the year ended Dec 31, 2023.
- The figure for the quarter ended Dec 31, 2025 ranks as the highest quarterly EBITDA Margin in data going back to the quarter ended Mar 31, 2024.
- Year over year, EBITDA Margin gained in two of the last four quarters, with an average year-over-year change of +1.15 percentage points.
- Per Business Quant data, the three quarters before the quarter ended Dec 31, 2025 came in at -17.69% (quarter ended Sep 30, 2025), 5.78% (quarter ended Jun 30, 2025) and 6.40% (quarter ended Mar 31, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 42.49% |
| 10 | Innocan Pharma | 5.78 Mn | 1.73 Mn | 4.43 Mn | 32.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 32.08% |
| Sep 30, 2025 | -17.69% |
| Jun 30, 2025 | 5.78% |
| Mar 31, 2025 | 6.40% |
| Dec 31, 2024 | 29.27% |
| Sep 30, 2024 | 4.19% |
| Jun 30, 2024 | 6.27% |
| Mar 31, 2024 | -17.76% |
API Access
Innocan Pharma EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=INNPF&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "INNPF", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=INNPF&period=max&api_key=YOUR_API_KEY");
const data = await res.json();